Literature DB >> 2861098

Characterization of dynorphin A-induced antinociception at spinal level.

S Spampinato, S Candeletti.   

Abstract

Dynorphin A (DYN A) injected intrathecally in the rat produced a significant elevation of the nociceptive threshold, measured by the tail flick test. The highest dose of DYN A (25 nmol) produced maximal elevation of tail flick latency to radiant heat together with hindlimb paralysis and tail flaccidity lasting several hours, thus confirming several previous reports. A lower dose of DYN A (12.5 nmol) produced only a smaller, not constant, short-lasting change in the nociceptive threshold. The vocalization test (electrical stimulation of the tail) gave a different result: the time course curve showed that the antinociceptive effect had worn off 60 min after DYN A 25 nmol. Thus it can be assumed that the prolonged depression of the tail flick reflex was related to motor dysfunction and did not completely reflect the animal's response to painful stimuli. Tolerance to the antinociceptive and motor effects developed after the chronic intrathecal infusion of DYN A with osmotic minipumps. Intrathecal MR 1452 (30 nmol), a purported kappa-receptor blocker, fully prevented the effects of DYN A but not morphine-induced antinociception. Naloxone antagonized DYN A only at a 4 fold higher dose. MR 1452 (90 nmol) administered after DYN A reversed the elevation of the vocalization threshold while tail flick latency remained unmodified. Analysis by high performance liquid chromatography of intrathecally injected radiolabelled DYN A revealed that DYN A was largely broken down about 10 min after its administration. Our results seem to indicate that DYN A in the spinal cord causes alterations in nociception and motor function, clearly distinguishable in time and both mediated by an opioid receptor, probably of the kappa type. However, different mechanism(s), possibly non-opioid in nature, may contribute to the prolonged depression of the tail flick.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861098     DOI: 10.1016/0014-2999(85)90024-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  On the selectivity of intravenous mu- and kappa-opioids between nociceptive and non-nociceptive reflexes in the spinalized rat.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

Review 2.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

3.  Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L.

Authors:  S Ferri; E Cavicchini; P Romualdi; E Speroni; G Murari
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 4.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

5.  Proceedings of the British Pharmacological Society. 9th-11th September 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

6.  Spinal antinociceptive actions of mu- and kappa-opioids: the importance of stimulus intensity in determining 'selectivity' between reflexes to different modalities of noxious stimulus.

Authors:  C G Parsons; P M Headley
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

Review 7.  The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors.

Authors:  M R Bruchas; B B Land; C Chavkin
Journal:  Brain Res       Date:  2009-08-28       Impact factor: 3.252

Review 8.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

9.  Effects of acute agonist treatment on subcellular distribution of kappa opioid receptor in rat spinal cord.

Authors:  Yulin Wang; Wei Xu; Peng Huang; Charles Chavkin; Elisabeth J Van Bockstaele; Lee-Yuan Liu-Chen
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

10.  kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat.

Authors:  G E Leighton; R E Rodriguez; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.